Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OK, what's up with the jump? No news stories anywhere?
They invested more than 100 million and they have a few results:
Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
Poniard Pharmaceuticals, Inc. (PARD) has received Clinical Trial Application (CTA) approval from the Chinese State Food and Drug Administration (SFDA) to conduct two Phase III clinical studies of its lead product candidate, picoplatin, in the treatment of second-line small cell lung cancer (SCLC) and second-line ovarian cancer in the People's Republic of China.
VSTM paid Poniard an upfront license fee and agreed to pay Poniard milestone payments of up to an aggregate of $13,250,000 upon the achievement of specified development and regulatory milestones.
And yes it’s gambling you do !! I own 13.500 shares av. 1.09. and hope to sell them for at least 1.50.
If I do not think that the products are sold alone ... very strange that, cres not you ...? or your door opens by itself?
And the costs of goods do not exist?, Think what you say makes no sense.
2 employees = little cost.
But they have a lot of products they can sell.
As can be optimistic with a company that has no employees and no revenue ..?
Every day we go a little bit higher.
0.56 0.05 +9.55%
I expect $1 before the end of september.
0.57 +0.11(+23.48%)
I expect big news before the end of the year.
High volume and:
PARD is trading in the range of $0.40 - $0.60 in the past 15 days.
Commodity Channel Index (CCI) is bullish for PARD.
PARD formed a bullish 5-day exponential moving average and 9-day exponential moving average crossover.
PARD formed a bullish Price & Exponential Moving Average Crossover signal.
PARD formed a bullish Price & Simple Moving Average Crossover signal.
PARD formed a bullish 5-day simple moving average and 10-day simple moving average crossover.
Our rating on the stock: VERY BULLISH with a score of 5/5.
P.S. I own 13.500 shares av. 1.09.
Thanks a lot,i have over 10000$,loosing 60%.I send to them a email,and no body replay me.Thank,again, to you.
Company terminated all of its employees on March 30, 2012, and has ceased substantially all of its operations.
From Form 8-K:
"The Company plans to seek short-term financing, which may be from a related party, to support minimal operations while the Company explores alternative sources of financing in order to continue its efforts to enter into an arrangement to support the continued development of its picoplatin product candidate."
No loger short PARD, watching it for now.....
PARD was a great short on the price spike in Nov.
This looks like its ready 2 bounce.
http://stockcharts.com/h-sc/ui?s=pard
Poniard Pharma (PARDD) and Allozyne terminate planned merger (PARD) 2.95 : Co announced that Poniard (PARDD) and Allozyne have mutually agreed to terminate the Agreement and Plan of Merger and Reorganization dated June 22, 2011. The termination follows the parties' determination that the common stock of the combined company resulting from the proposed merger will not qualify for listing on The Nasdaq Capital Market, which is a condition to closing of the merger. Poniard's board of directors is actively exploring alternatives for Poniard's business and assets.
Still think selling is tax based...?
Thank you!
Happy New Year 2012!!
Tax loss selling season until the end of next week, bottom, there may be no bottom until then.
What's the real value after this merger??
Have you figger it out?
PARD likely going lower with tax loss selling a down market into Jan.
Never a rebound? Where's the botom???
Down she go. No hope here?
What happens with the PPS after the Merger with ..... ???
PARDD now, 6.26$, chart in
http://stockcharts.com/h-sc/ui?s=pardd
Poniard Pharma announces shareholders approve merger with Allozyne (PARD) 0.22 -0.04 : Co announced that its shareholders have approved proposals to complete the previously announced merger with Allozyne including the issuance of shares of Poniard common stock and resulting change of control of Poniard resulting from the merger and effecting a 1-for-40 reverse stock split of Poniard common stock.
The early morning is looking good so far..
It will be interesting to see where this one goes tomorrow..
That's right, the vote is on Nov. 21st. Looking through the last quarterly report, this isn't the first time this year they've voted to do a R/S. They didn't have enough votes last time...
I doubt it will happen again as the merger with Allozyne is depending on regaining compliance with Nasdaq regulations.
"The Company adjourned its reconvened annual meeting of shareholders on July 22, 2011, with an insufficient number of votes to approve the reverse stock split proposal. Although 91.6% of the shareholders who voted at the annual meeting voted in favor of the reverse stock split proposal, those shareholders held only 49.2% of the Company’s common stock outstanding and entitled to vote. A majority (50% plus one share) of the Company’s common stock outstanding and entitled to vote was required to approve the reverse stock split proposal. On July 19, 2011, the Company received a letter from the Staff advising that the Company has not regained compliance with the $1.00 per share minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) and, unless the Company requests an appeal of this determination, the Company’s common stock would be delisted from The Nasdaq Capital Market. On August 25, 2011, representatives of the Company attended a hearing to appeal the Staff decision and to present a plan for compliance. On September 2, 2011, the Nasdaq Hearings Panel determined to allow the continued listing of the Company’s common stock on The Nasdaq Capital Market subject to the conditions that, on or before December 31, 2011, the Company must have (i) held a shareholders’ meeting; (ii) obtained shareholder approval for the merger ."
I think monday is when they vote to decide if the r/s is the way they want to go. could be wrong though, I just skimmed through it friday.
Even if the R/S goes thru, its not bad thing for this company as I believe its priced in already. They are doing it to acquire or merge with allozyne. It's not a usual .r/s. Two things you should consider, the current market cap of Pard and the people coming onboard, not to forget, a drug similar to biogen.Although we could be pleasantly surprised if there is more news and we get above a dollar without a reverse split.
PARD, 1 for 40 R/S news:
PR released on Nov 7:
SAN FRANCISCO, CA--(Marketwire -11/07/11)- Poniard Pharmaceuticals, Inc. (NASDAQ: PARD - News) announced today that Glass, Lewis & Co., a leading independent proxy advisory firm, has recommended that Poniard shareholders vote "FOR" all proposals listed in the Company's proxy statement materials, including the proposal related to the issuance of stock in connection with Poniard's proposed merger with ALLOZYNE, Inc. and the proposal to effect a 1-for-40 reverse stock split of Poniard's outstanding common stock.
$PARD looking like it could gap on Monday, some short selling at the end.
How long have you been following the story? There is so much more to it than just that. The 10000 shares is of a non-operating entity with intellectual property, They are planning a reverse merger with a much larger privately owned corporation of unkown value, and deep pockets. PARD shareholders will retain 35% of the new company. In order to stay listed on nasdaq market, the share price has to come back above a certain level, and a reverse split will bring the share price to that level. Cry dilution if you like, but that's not what is going on here. The Intellectual property of Poniard is valuable, they just didn't have the money burn that it requires to get their products through the regulatory process. Now they have a new partner, and the partner has the resources that is necessary to get things moving. Not only that, but the new partner desires to be publicly traded. 35% Is much greater than average. The new partner has an entire pipeline of product candidates of its own as well. Things are looking up for good old Poniard Pharmaceuticals.
When did they announce a reverse split?
couldn't break .30 after it fell below it from the HOD. hope it pops monday.
Your 10k shares will go to 250 shares, with 1 for 40 Huge Reverse split.
these tiny sells keep knocking it down! frustrating
PARD, What a joking $250k payment! Will do 1 for 40 Reverse Split, Huge!!!
Agreed. All Aboard!!
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
552
|
Created
|
05/31/07
|
Type
|
Free
|
Moderators |
http://www.poniard.com/
http://finance.yahoo.com/q/h?s=PARD
http://www.secform4.com/insider-trading/755806.htm
Poniard Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of cancer therapy products in the United States. Its lead product is Picoplatin, a platinum-based cancer therapy, designed to overcome platinum resistance in the treatment of solid tumors. Picoplatin is in Phase II clinical trails in small cell lung cancer and is in Phase I/II trials for colorectal and hormone-refractory prostate cancers. The company has a collaboration agreement with The Scripps Research Institute on the discovery of novel, small-molecule, and multi-targeted protein kinase inhibitors and focal adhesion kinase inhibitors as therapeutic agents, including for the treatment of cancer. Poniard Pharmaceuticals was founded in 1984. It was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in 2006. The company is headquartered in South San Francisco, California.
[
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |